The CEASE-AF trial highlights Hybrid ablation’s impressive long-term durability, showing a ~33% improvement in freedom from atrial arrhythmias* over 24 months for patients with long-standing persistent Afib**. Learn more about the compelling data behind Hybrid AF™ Therapy at <a href='https://www.linkedin.com/feed/hashtag/?keywords=AHA2024.&highlightedUpd…; target='_blank'>#AHA2024.</a>​
​
In the meantime, explore further here: <a href="https://okt.to/qy0uc3&quot; target="_blank">https://okt.to/qy0uc3</a&gt; ​
​
*Freedom from atrial arrhythmias (atrial fibrillation, atrial flutter, atrial tachycardia) off anti-arrhythmic drugs (AADs) except previously failed AADs at doses not exceeding those previously failed​​
**Persistent atrial fibrillation with enlarged left atrium and longstanding persistent Afib​​